CAR-T Therapy for Lymphoma Patients with Liver Cirrhosis
Author Information
Author(s): Kong Danqing, Ping Nana, Zhu Qian, Zhang Xiao, Li Junhong, Zou Rui, Wu Depei, Jin Zhengming, Qu Changju
Primary Institution: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University
Hypothesis
Can CAR-T therapy be safely and effectively used in DLBCL patients with hepatitis B-related cirrhosis?
Conclusion
CAR-T therapy is effective for treating DLBCL patients with HBV-related cirrhosis, but requires careful monitoring for liver complications.
Supporting Evidence
- All three patients achieved complete remission after CAR-T therapy.
- The progression-free survival rate was 100% after a median follow-up of 42 months.
- Patients experienced complications related to cirrhosis, including HBV reactivation.
Takeaway
Doctors used a special treatment called CAR-T therapy to help three patients with a type of blood cancer and liver problems, and it worked well for them.
Methodology
Three patients with relapsed/refractory DLBCL and HBV-related cirrhosis were treated with CAR-T therapy and monitored for outcomes and complications.
Potential Biases
Potential bias due to the small sample size and retrospective nature of the study.
Limitations
The study includes a small number of cases and lacks long-term follow-up data.
Participant Demographics
Two male and one female patient, aged 46 to 62 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website